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Peramivir is a novel cyclopentane neuraminidase inhibitor of influenza virus. It was
approved by the Food and Drug Administration in December 2014 for treatment of
acute uncomplicated influenza in patients 18 years and older. For several months prior
to approval, the drug was made clinically available under Emergency Use authorization
during the 2009 H1N1 influenza pandemic. Peramivir is highly effective against human
influenza A and B isolates as well as emerging influenza virus strains with pandemic
potential. Clinical trials demonstrated that the drug is well-tolerated in adult and pediatric
populations. Adverse events are generally mild to moderate and similar in frequency to
patients receiving placebo. Common side effects include gastrointestinal disorders and
decreased neutrophil counts but are self-limiting. Peramivir is administered as a single-
dose via the intravenous route providing a valuable therapeutic alternative for critically
ill patients or those unable to tolerate other administration routes. Successful clinical
trials and post-marketing data in pediatric populations in Japan support the safety and
efficacy of peramivir in this population where administration of other antivirals might not
be feasible.
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INTRODUCTION
Influenza virus infections cause significant morbidity and mortality during annual outbreaks and
result in large economic losses due to healthcare costs and loss of productivity (Nicholson et al.,
2003). These outbreaks occur during the winter season in countries with temperate weather and
during rainy seasons in tropical countries (Tamerius et al., 2010). Influenza pandemics periodically
occur due to the emergence of antigenically novel influenza viruses in humans and can pose a
threat for higher morbidity and mortality rates than seasonal outbreaks (Salomon and Webster,
2009). In the last century four major pandemics have occurred: the Spanish influenza (1918), the
Asian influenza (1957), the Hong Kong influenza (1968), and the 2009 H1N1 pandemic influenza
(H1N1pdm09; Cox and Subbarao, 2000). Currently, several avian-origin influenza strains carry
pandemic potential (Abdelwhab and Hafez, 2011; Tan et al., 2015). So far, influenza control efforts
have focused on vaccines and antiviral therapies that target different components of the virus or
host factors.
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Influenza viruses belong to the Orthomyxoviridae family with
two types, A and B, which are the cause of major outbreaks in
humans. Influenza viruses have negative-sense, single-stranded,
segmented RNA genomes and possess three membrane proteins,
the hemagglutinin (HA), the neuraminidase (NA), and the matrix
protein (M2; McGeoch et al., 1976; Palese and Schulman, 1976;
Palese, 1977). The HA protein mediates sialic acid-conjugated
cell receptor recognition, receptor binding, and fusion-mediated
entry into cells (Sauter et al., 1992; Hamilton et al., 2012). The
M2-channel (proton pump) facilitates release of viral RNA into
the cytoplasm by acidifying the virus interior (de Vries et al.,
2011). Virus replication commences in the nucleus and virus
assembly occurs at the cell membrane (Leser and Lamb, 2005;
Banerjee et al., 2013). The NA protein facilitates the release of
newly assembled virus particles by cleavage of sialic acid residues
(Colman, 1994). The NA also promotes virus movement through
airway mucus thereby enhancing its infectivity (Yang et al., 2014).
Influenza A viruses are highly diverse with 16 HA and 9 NA
subtypes identified thus far (Salomon and Webster, 2009). Wild
aquatic birds are the main reservoir for influenza A viruses, which
can also infect many other hosts, including humans (Webster
et al., 1992). Furthermore, bats have recently been identified
as the reservoir for two novel influenza-like subtypes (H17N9
and H18N10; Tong et al., 2012, 2013; Wu et al., 2014). Two
influenza A subtypes (H1N1 and H3N2) and two influenza B
strains (Yamagata and Victoria) are the major subtypes that cause
annual outbreaks in humans (Nicholson et al., 2003). However,
several avian influenza subtypes (e.g., H5N1, H7N9, and H9N2)
have caused human infections and pose a pandemic threat should
they adapt and acquire aerosol transmissibility among humans
(Alexander et al., 2009; Abdelwhab and Hafez, 2011; Lam et al.,
2015).
Influenza vaccines and antiviral drugs are effective in
preventing infections or ameliorating disease severity (Osterholm
et al., 2012). Live-attenuated and inactivated vaccines are
available for prevention of influenza (Krammer and Palese, 2015).
Two antiviral groups, M2 channel blockers and neuraminidase
inhibitors (NAIs) are available for treatment and prevention
of influenza infections (Jefferson et al., 2001; Stoll et al., 2003;
Burnham et al., 2013). The emergence of high levels of M2
channel blocker resistance (Hata et al., 2007; Ison, 2011), have
made NAIs the drugs of choice for prevention and treatment
of influenza infections. Antivirals have an advantage over
vaccines as they are readily available in case of the emergence
of novel influenza viruses, for which the development of an
effective vaccine would take several months (Wong and Webby,
2013). This was clearly demonstrated with the H1N1pdm09
emergence in 2009 during which the antiviral drug, oseltamivir,
was heavily utilized while a vaccine was under development
(Miller et al., 2013). Recently licensed by the Food and Drug
Administration (FDA; McLaughlin et al., 2015), peramivir
(BCX-1812 and RWJ-270201) is the latest addition to the
already of approved NAIs, oseltamivir and zanamivir (Ison,
2011). Peramivir is administered intravenously providing an
alternative access to patients unable to take medication via
the oral (oseltamivir) or inhalation (zanamivir) routes. This
review will focus on the development, efficacy, and safety of
peramivir. In vitro and in vivo efficacies and pharmacokinetics
data as well as emergence of resistance to antivirals will also be
discussed.
DESIGN AND MODE OF ACTION OF
PERAMIVIR
The active site of influenza virus NA enzyme is made up of 18
highly conserved residues (Colman, 1994). The catalytic site is
made up of eight residues (R118, D151, R152, R224, E276, R292,
R371, and Y406 in N2 numbering) that directly interact with
the substrate (sialic acid) and participate in its catalysis. The
framework site, made up of 11 residues (E119, R156, W178, S179,
D/N198, I222, E227, H274, E277, N294, and E425), provides a
structural framework support for the catalytic residues (Colman
et al., 1983, 1993; Burmeister et al., 1992; Gubareva et al., 2001).
Influenza A virus lacking the NA protein is able to infect cells
but progeny viruses aggregate and fail to be released from the
cell-surface (Liu et al., 1995). Similarly, blocking the enzymatic
activity of the NA protein by NAIs results in the formation of
virus aggregates and prevents the release of the virus from the cell
surface (Palese and Compans, 1976). Elucidation of the structure
and mechanism of action of the NA have made structure- and
mechanism-based design of NAIs possible (Colman, 1994; Stoll
et al., 2003; von Itzstein, 2007). These data have led to the
identification of several potent NA inhibitors including three
that have been approved for clinical use [peramivir (Babu et al.,
2000), oseltamivir (Kim et al., 1997), and zanamivir (von Itzstein
et al., 1993)] and one that is still under development [laninamivir
(Yamashita et al., 2009), currently only approved in Japan;
Table 1].
Peramivir was designed using crystallographic screening of
enzyme-bound compounds containing a mixture of isomers
to detect the most active isomer (Babu et al., 2000). It is a
novel cyclopentane that is structurally distinct from other NAIs.
It has a C4-guanidino substitution and a hydrophobic side
chain, resembling zanamivir and oseltamivir, respectively, to
take advantage of both hydrophilic pockets of the NA enzyme
(Figures 1 and 2) (Kim et al., 1997; Babu et al., 2000; Malaisree
et al., 2008). These substitutions allow tight interactions between
peramivir and the enzyme active site. The negatively charged
carboxylate group forms eight strong hydrogen bonds with a triad
of conserved arginine residues (R118, R292, and R371) compared
to only six bonds for oseltamivir and zanamivir. The methyl
group of the acetamido occupies the hydrophobic pocket formed
of residues W178 and I222, whereas the oxygen and nitrogen
atoms form hydrogen bonds with Arg152 and a bound water
molecule. The guanidino group fills the fourth pocket, forming
stable hydrogen bonds and electrostatic interactions with the
acidic groups of E119, D151, and E227 and replacing the existing
water molecule in this pocket (Babu et al., 2000; Shetty and Peek,
2012). These interactions and the extra bonds formed between
peramivir and its target, allow peramivir to tightly bind the NA
active site and to have a slow dissociation-rate (t1/2 > 24 h) in
comparison to oseltamivir and zanamivir (t1/2 = 1.25 h; Bantia
et al., 2006).
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TABLE 1 | Neuraminidase inhibitors currently approved or undergoing clinical trials for treatment and prophylaxis against influenza.
Drug Code name Chemical name Brand name Company Route Approval year Reference1
Oseltamivir GS4104 ethyl (3R,4R,5S)-4-acetamido-5-
amino-3-pentan-3-
yloxycyclohexene-1-
carboxylate;phosphoric
acid
Tamiflu R© Roche Oral 1999 Kim et al.,
1997
Zanamivir 139110-80-8 (2R,3R,4S)-3-acetamido-4-
(guanidino)-2-[(1R,2R)-1,2,3-
trihydroxypropyl]-3,4-dihydro-2H-
pyran-6-carboxylic
acid
Relenza R© GlaxoSmithKline Oral
inhalation
1999 von Itzstein
et al., 1993
Peramivir BCX-1812 and
RWJ-270201
(1S,2S,3S,4R)-3-[(1S)-1-
acetamido-2-ethylbutyl]-4-
(diaminomethylideneamino)-2-
hydroxycyclopentane-1-carboxylic
acid
Rapivab R© BioCryst Intravenous 2014 Babu et al.,
2000
Laninamivir R-125489 (2R,3R,4S)-3-acetamido-4-
(guanidino)-2-[(1R,2R)-2,3-
dihydroxy-1-methoxypropyl]-3,4-
dihydro-2H-pyran-6-carboxylic
acid
Inavir R© Daiichi
Sankyo/Biota
Oral
inhalation
−2 Yamashita
et al., 2009
1Details on nomenclature and structure can be found at https://pubchem.ncbi.nlm.nih.gov
2Laninamivir was granted approval for clinical use in Japan in 2010 and is currently used in clinical practice.
FIGURE 1 | Chemical structure of peramivir.
In vitro activity of peramivir has been investigated against
human and avian influenza A and B viruses (Babu et al.,
2000; Bantia et al., 2001; Govorkova et al., 2001; Gubareva
et al., 2001; Ikematsu et al., 2014, 2015a,b; Leang et al., 2014;
Zaraket et al., 2014). These studies have consistently shown that
peramivir possesses comparable or superior inhibitory activity
against influenza A and B viruses as oseltamivir, zanamivir,
and laninamivir. Influenza B isolates have been shown to be
intrinsically less susceptible in vitro to oseltamivir compared to
H1N1 and H3N2 viruses (Zaraket et al., 2010, 2014; Ikematsu
et al., 2014, 2015a,b). Notably, peramivir shows improved in vitro
activity against influenza B isolates compared to oseltamivir or
zanamivir. The IC50 (50% inhibitory concentration) values of
peramivir against influenza B were reported to be several folds
lower than those of the rest of the NAIs (Dapat et al., 2010;
Ikematsu et al., 2014, 2015a,b; Zaraket et al., 2014). Importantly,
peramivir has been also demonstrated to be highly effective
in vitro against emerging avian influenza viruses of pandemic
potential including H5N1, H7N9, and H9N2 (Govorkova et al.,
2001; Zhang et al., 2014; Marjuki et al., 2015).
OTHER INFLUENZA VIRUS INHIBITORS
Aside from NA, at least four other viral targets have been
identified for drug design based on their functions. These include
the HA (Sauter et al., 1992; Mammen et al., 1995), the M2
(Hay et al., 1986), the polymerase (PB1, PB2, and PA; Hastings
et al., 1996), and the NP (Tompkins et al., 2004) proteins.
Furthermore, research focused on targeting host proteins and
signaling pathways that play a role during influenza virus lifecycle
is underway (Edinger et al., 2014).
Inhibitors targeting the HA protein can be divided into
two groups based on their mode of action: (1) inhibitors
directly targeting the HA protein, and (2) inhibitors indirectly
targeting the HA protein (Li et al., 2015). The first group
includes peptides and small molecules that interact with the
HA molecule to inhibit the HA-mediated membrane fusion step
(Jones et al., 2006; Zhu et al., 2011; Basu et al., 2014; White
et al., 2015). It also contains molecules that bind to the HA
protein disrupting its interaction with sialic acid receptors and
preventing the virus from binding to the cell (Matsubara et al.,
2010; Chen et al., 2015). This group also includes surfactant D
and other collectins that bind to oligosaccharides on the HA
molecules, hindering receptor binding (Hartshorn et al., 2008).
The second group of HA inhibitors include molecules that inhibit
host proteolytic enzymes (e.g., kallikrein-peptidases) necessary
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FIGURE 2 | Peramivir bound to influenza A/H7N9 neuraminidase. Crystal structure of peramivir and influenza A/H7N9 neuraminidase complex (4 MWV). The
four binding pockets of the enzyme active site are shown in yellow shades.
for cleavage-activation of the HA protein or molecules that
inhibit V-ATPase dependent endosomal acidification necessary
for the HA fusion-activation step (Chen et al., 2013; Leu et al.,
2015).
Attempts to develop new M2-channel blockers are underway;
however, these compounds seem to be inactive against mutants
resistant to existing M2 inhibitors (Balgi et al., 2013). Polymerase
inhibitors are highly effective against influenza virus replication
(DuBois et al., 2012; Furuta et al., 2013). The most prominent
drug of this group is favipiravir (T-705), a purine analog
inhibitor of the viral RNA polymerase (Furuta et al., 2005;
Baranovich et al., 2013). Favipiravir holds promise not only as
an influenza antiviral but also against many other RNA viruses
(Furuta et al., 2013). NP inhibitors include short interfering
RNAs targeting conserved regions of the NP gene (Tompkins
et al., 2004) or small molecules that inhibit oligomerization and
subsequent nuclear import of the NP protein (Semenova et al.,
2010).
In addition to drugs targeting viral proteins, several
therapeutics targeting host factors are under development. Host-
targeting drugs have the advantage of not selecting changes
in the virus that could lead to resistance. Fludase (DAS18), a
recombinant fusion protein composed of a sialidase catalytic
domain derived from Actinomyces viscosus fused with a cell
surface-anchoring sequence, cleaves sialic acid receptors from the
airway epithelia, thus preventing virus attachment and infection
(Malakhov et al., 2006). Nitazoxanide (NT-300), originally
developed and licensed as antiprotozoal agent, is currently
developed as a first-in-class broad-spectrum antiviral agent and
is efficacious in reducing duration of influenza infection in
Phase 2b/3 clinical trial (Haffizulla et al., 2014; Rossignol, 2014).
Nitazoxanide inhibits influenza virus replication by blocking
post-translational maturation of the viral HA protein (Rossignol
et al., 2009). Despite the constant development of various
influenza virus inhibitors, the rapid evolution of the virus makes
resistance a compelling challenge.
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DRUG RESISTANCE
In 2007 and 2008, high levels of oseltamivir resistance among
seasonal H1N1 viruses emerged worldwide undermining the
efficacy of this drug. Nonetheless, post-pandemic 2009 influenza
A and B viruses remain largely susceptible to NAIs (Ikematsu
et al., 2014, 2015b; Leang et al., 2014; Meijer et al., 2014;
Takashita et al., 2014; Zaraket et al., 2014). The prevalence
of peramivir-resistance among influenza A/H1N1pdm09 viruses
ranges between 1.3 and 3.2% and is <1% among influenza
A/H3N2 and B viruses (Leang et al., 2014; Meijer et al.,
2014; Takashita et al., 2014). Gubareva et al. (2001) have
suggested that while resistant variants with mutations in the
enzyme framework can retain susceptibility to other NAIs,
those in the functional or catalytic residues tend to cause
cross-resistance to all NAIs. Their study demonstrated that
the most commonly detected H274Y (H275Y N1 numbering)
framework mutation conferring resistance to oseltamivir results
in cross-resistance to peramivir but not to zanamivir (Gubareva
et al., 2001). This mutation has been shown to rapidly
emerge upon intravenous (IV) treatment with peramivir in
immunocompromised or hematopoietic cell transplant recipients
(Memoli et al., 2010; Renaud et al., 2010). Nonetheless, in
contrast to oral oseltamivir, the efficacy of peramivir against
the H1N1 H274Y variant has been demonstrated in vivo upon
single or multiple-intramuscular (IM) or IV regimens in mice,
suggesting that peramivir could be used against oseltamivir-
resistant H274Y influenza virus infections (Abed et al., 2011,
2012). Human influenza B isolates with H273Y mutation in the
NA active site were found to be resistant to both oseltamivir and
peramivir but not zanamivir (Higgins et al., 2012). Resistance
to peramivir due to HA mutations has also been described
in vitro (Smee et al., 2001). Serial passages of an H3N2 virus
in the presence of peramivir caused selection of peramivir-
resistant viruses linked to a K189E mutation in the HA
protein.
The zanamivir-resistant influenza A/H3N2 variants with
framework E119G or E119A mutations remain susceptible to
peramivir and oseltamivir (Gubareva et al., 2001). Using reverse
genetics, it was shown that these two mutations, as well as the
E119D substitution, induce resistance to zanamivir but not to
peramivir or oseltamivir in the H1N1pdm09 virus background
(Baek et al., 2015). Surprisingly, laboratory generated H5N1 virus
with the E119D mutation possessed high level of resistance to all
NAIs. While the E119V mutation in the H3N2 context conferred
resistance to oseltamivir only (Meijer et al., 2014). In influenza B,
an R152K catalytic site mutation caused cross-resistance to all of
the three NAIs (peramivir, oseltamivir, and zanamivir; Gubareva
et al., 2001). In contrast, an H1N1pdm09 virus with this mutation
remains sensitive to all three approved NAIs (Baek et al., 2015).
Zanamivir-resistant influenza B R292K variant was found to be
extremely resistant to oseltamivir but was moderately resistant to
peramivir (Gubareva et al., 2001; Meijer et al., 2014).
Resistance to NAIs seems to arise easily among emerging
influenza viruses as well. Itoh et al. (2015) reported the emergence
of H7N9 influenza A virus with a R289K NA mutation conferring
resistance to oseltamivir and peramivir upon NAI treatment in
non-human primates. H7N9 viruses continue to cause human
infections posing a pandemic threat (Zhu et al., 2016). The
emergence of resistance among these viruses is a reason for
concern.
Azuma et al. (2015) reported the presence of peramivir and
laninamivir in high concentrations in sewage eﬄuent and river
waters in Japan. This could result in passive exposure of wild
birds to these NAIs and give rise to the emergence of NAI-
resistance. This could be especially the case during pandemics
which trigger high consumption levels of NAIs. Maintaining
the efficacy of new and old antiviral drug inhibitors requires
continuous monitoring of the susceptibility of circulating and
emerging influenza viruses. Additionally, the ease and potential
for emergence of NAI-resistant influenza viruses highlights the
importance of assessing combination antiviral treatments for
influenza (Govorkova and Webster, 2010). Combining antivirals
targeting different influenza viral proteins and/or host molecules
can hinder the emergence of resistance.
PRECLINICAL STUDIES
Numerous studies have demonstrated the efficacy of peramivir
against human and emerging influenza viruses in vivo
(Govorkova et al., 2001; Sidwell et al., 2001a; Sweet et al.,
2002; Barroso et al., 2005; Bantia et al., 2006, 2011; Boltz
et al., 2008; Abed et al., 2012). Earlier studies focused on
assessing the oral efficacy of peramivir in comparison with
oseltamivir and zanamivir treatment. Prophylactic peramivir
treatment administered at a 10 mg per/kg/day by oral gavage
twice daily for 5 days reduced lung viral load and provided
complete protection against lethal challenge with H5N1 and
H9N2 viruses in mice, similar to oseltamivir and consistent
with the in vitro efficacies of these drugs (Govorkova et al.,
2001). Similar levels of protection were demonstrated with
prophylactic peramivir administration of 1–10 mg/kg/day
twice daily for 5 days against H1N1, H3N2, and H6N2 viruses
(Babu et al., 2000; Bantia et al., 2001; Sidwell et al., 2001a,b).
Oral peramivir also significantly inhibited mortality in mice
infected with influenza B virus (Sidwell et al., 2001b). Studies
in ferrets suggested that 3- to 10-fold higher peramivir doses
than those used in mice were needed to significantly reduce
virus shedding in nasal washes and reduce inflammatory
response in an H3N2 challenge model (Sweet et al., 2002).
It remained unclear whether these differences were host-
dependent or due to the different H3N2 strains used in each
host.
Pharmacodynamics studies in mice demonstrated that the
antiviral effect of peramivir was independent of the schedule
used and recommended once-daily dosing as the basis for future
drug evaluations (Drusano et al., 2001). Further studies showed
that delayed oral administration of peramivir 48 h after H5N1
infection resulted in 50% reduced mortality in mice (Govorkova
et al., 2001). In contrast, Bantia et al. (2001) reported failure
of delayed treatment of H6N2 infected mice at 48 h after
infection and found that full protection required initiation of
treatment at 24 h after infection. Another study found that oral
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treatment with peramivir could be delayed at least 60 h after
virus exposure and still prevent mortality in H1N1 infected mice,
however, administration at 24 h after exposure provided the
greatest suppression of lung virus titers (Sidwell et al., 2001b).
Delayed oral peramivir treatment was also shown to be effective
in immunosuppressed mice infected with H1N1 virus (Sidwell
et al., 2001a). These studies emphasize the importance of accurate
diagnosis and early initiation of the treatment for optimal drug
efficacy.
Despite the well-established efficacy of oral peramivir in
animal studies, human clinical trials resulted in less success due
to low oral bioavailability (Barroso et al., 2005). Thus, further
efforts were focused on exploring the parenteral route. The
first study investigating the IM route in mice infected with
H1N1 or H3N2 viruses demonstrated that a single, prophylactic
or delayed, 10–20 mg/kg dose significantly reduced morbidity
(measured by weight loss) and mortality similar to the 5-day
regimen of oral peramivir (Bantia et al., 2006). This efficacy
was unmatched by IM-administered oseltamivir, which failed
to provide any protection. Additionally, both prophylactic and
delayed treatments with a single IM peramivir injection were
effective against H1N1pdm09 infection in mice (Bantia et al.,
2011).
In the case of a peramivir-resistant H1N1 virus with the
H274Y mutation, multiple IM doses demonstrated superior
efficacy in comparison to single IM dose regimens administered
as a prophylaxis in a mouse challenge model (Abed et al.,
2010). IM peramivir, single and multiple doses, prevented
mortality in peramivir-resistant H1N1-infected mice when it
was administered at 24 or 48 h post-infection (Abed et al.,
2012). Nonetheless, mice receiving peramivir IM injection at
24 h post-infection exhibited less weight loss compared to when
treatment was delayed by 48 h. Post-exposure IM peramivir
treatment also mitigated the disease and reduced the infectious
virus titers promoting survival of mice infected with the highly
pathogenic H5N1 influenza virus, although multiple doses were
needed (Boltz et al., 2008; Yun et al., 2008). Contrary to the
effectiveness of a single IM dose used to treat low pathogenic
viruses like H1N1 (Bantia et al., 2006), a single IM injection of
peramivir administered 1 h post-inoculation with a lethal H5N1
virus resulted in only 33% survival in mice (Boltz et al., 2008).
Survival improved to 55% with two IM peramivir doses. An
8-day regimen consisting of two daily IM injections starting 1 h
post-exposure followed by seven daily IM doses provided mice
with 100% protection from lethal H5N1 challenge, but survival
decreased to 78 and 56% when treatment was delayed by 24
and 48 h, respectively (Boltz et al., 2008). The 8-day regimen of
30 mg/kg/day IM peramivir, with the first dose initiated at the
time of infection, also resulted in reduction of lung virus titers
and mortality in mice infected with a lethal dose of the H7N9
virus (Farooqui et al., 2015).
Combination regimens of IM peramivir with oseltamivir
or amantadine performed better than peramivir monotherapy
against H1N1 and H3N2 viruses (Bantia et al., 2010; Smee et al.,
2010). In addition, IM peramivir treatment coupled with oral
favipiravir was more effective and a reduced dose was needed
than in monotherapy against peramivir-resistant H1N1pdm09
virus (Park et al., 2014). Nonetheless, in the aforementioned
studies, a 5-day regimen was used to test the combination therapy
(Bantia et al., 2010; Smee et al., 2010; Park et al., 2014). Therefore,
further research is needed to elucidate the effect of the approved
single-dose treatment of peramivir in combination with other
antiviral drugs.
Consistent with the effectiveness of the IM regimen, multiple
studies demonstrated the efficacy of single IV injection of
peramivir in animal models (Kitano et al., 2011; Kakuta et al.,
2013). A single IV administration of 30 mg/kg peramivir resulted
in significant reduction of nasal virus titers and clinical symptoms
in ferrets and cynomolgus macaques infected with a recent
influenza B virus strain, even when treatment was delayed
up to 48 h post-infection (Kitano et al., 2011). IV peramivir
administered as a single-dose of 30 mg/kg and 13 h after infection
of mice with influenza A/H1N1 or B viruses showed significant
reduction in mortality and lung viral loads, an effect that was
similar to laninamivir (Kakuta et al., 2013). Immunosuppressed
mice infected with the H1N1pdm09 virus required 10–20 days of
daily IV peramivir to attain>80% survival, whereas a single-dose
regimen was non-efficacious (Kitano et al., 2013). By contrast,
repeated oral administration of oseltamivir (5 mg/kg twice daily
for 20 days) failed to show any improvement in survival of
infected immunosuppressed mice despite significantly reducing
weight loss.
Repeated IV administration of peramivir over 5 days starting
on the day of infection or 24 h after infection significantly reduced
viral titers, inflammatory cytokines, and the period to virus
clearance in the upper respiratory tract of cynomolgus macaques
infected with H5N1 virus (Kitano et al., 2014).
Single and repeated IV peramivir administration was also
shown to inhibit virus replication and proinflammatory immune
responses in mice co-infected with H1N1pdm09 virus and the
bacterium Streptococcus pneumonia, consequently leading to
earlier bacterial clearance and significantly improved survival
(Onishi et al., 2015; Tanaka et al., 2015). Outcomes of bacterial
superinfection were significantly improved after a multiple-
dose regimen of IV peramivir compared to single-dose IV
peramivir or multiple oral doses of oseltamivir. Initiating
treatment just after viral infection resulted in better outcomes
than delaying treatment even if treatment was started before
bacterial superinfection (Onishi et al., 2015). Therefore, quickly
beginning peramivir administration after symptoms onset is
important not only to resolve influenza virus infection, but also
to prevent complications due to a subsequent bacterial infection.
Overall, animal experiments demonstrated that peramivir is
as effective and in some cases more effective than other NAIs.
Its safety profile in animal models and the efficacy of the single-
dose regimen makes it an attractive treatment choice for influenza
infections.
CLINICAL STUDIES
Pharmacokinetics
Experimental clinical data revealed that oral peramivir is rapidly
absorbed with plasma levels beginning to rise within 1 h of
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administration, and the maximum concentration (Cmax) being
achieved in 2.5 h (range: 2–4 h; Young et al., 2001; Barroso
et al., 2005). However, oral peramivir formulation showed low
bioavailability (≤3%) in humans despite the use of relatively high
doses. Peak plasma levels were ∼100 ng/ml and ∼200 ng/ml
after four doses of 400 and 800 mg oral peramivir, respectively
(Barroso et al., 2005). This warranted the study of parenteral
formulations which resulted in high drug concentrations in
the blood (Boltz et al., 2008). The peak plasma concentrations
for IM and IV peramivir (10,000–20,000 ng/mL) are nearly
two orders of magnitude higher than those achieved with
standard doses of oral oseltamivir (Hayden, 2009; Kohno et al.,
2010).
The pharmacokinetics (PK) of IV peramivir were evaluated
in Phase I trials in adults (Food and Drug Administration,
2015b). These trials demonstrated a linear relationship between
dose and drug exposure parameters (area under the curve
[AUC] and Cmax; Mancuso et al., 2010; Food and Drug
Administration, 2015b). Plasma concentrations of IV peramivir
peaked immediately after administration (Whitley et al.,
2014; Yoshino et al., 2015). At the end of a 30 min IV
infusion of a single-dose of 600 mg peramivir, Cmax reached
46,800 ng/mL and AUC was 102,700 h× ng/mL (Food and Drug
Administration, 2015b). Kohno et al. (2011a) assessed median
plasma concentrations upon IV administration of single 300 or
600 mg doses over a period of 15–60 min to high-risk patients
(poorly controlled diabetes, chronic respiratory tract disease,
and drug-induced immunosuppression). The median plasma
concentration immediately before the end of the infusion was
25,500 ng/mL in the 300 mg group and 51,500 ng/mL in the
600 mg group. Moreover, 3–9% of peramivir was detected in
the nasal cavity and pharyngeal mucus of healthy subjects upon
IV administration of 600 mg dose. The drug concentration in
pharyngeal mucus was 5,280 nM at 2 h and 220 nM at 12 h
after administration, well above its IC50 values (Kohno et al.,
2011a). Based on a population pharmacokinetic analysis, the
central volume of distribution was 12.56 L (Food and Drug
Administration, 2015b).
Despite a low in vitro plasma protein binding of less than
30% (Chairat et al., 2013; Food and Drug Administration, 2015b),
the elimination half-life of peramivir following a single IV
administration of 600 mg to healthy subjects is approximately
20 h (Boltz et al., 2008; Hayden, 2009; Ison et al., 2013; Food
and Drug Administration, 2015b). Together with the slow NA
dissociation rate (Bantia et al., 2006), the prolonged half-life
allows for infrequent dosing regimens.
Peramivir is not significantly metabolized by the liver in
humans. The drug is not a substrate for CYP enzymes,
does not affect glucuronidation, and is not a substrate or
inhibitor of P-glycoprotein mediated transport (Food and Drug
Administration, 2015b). Thus, dose adjustment is unnecessary in
hepatic impairment (Chairat et al., 2013).
Peramivir is almost entirely eliminated by renal excretion
with 90% of the drug excreted unchanged (Mancuso et al., 2010;
Chairat et al., 2013; Food and Drug Administration, 2015b).
Negligible accumulation was observed following multiple doses,
either once or twice daily for up to 10 days (Food and Drug
Administration, 2015b). Clearance of peramivir is similar to the
average creatinine clearance (CrCl) for a 70 kg adult with normal
renal function (Clay et al., 2011). This suggests that peramivir
is excreted mainly by glomerular filtration. Moreover, CrCl was
found to be the most important factor affecting peramivir PKs
(Matsuo et al., 2015). Data from six clinical studies in Japan
and the United States including healthy volunteers and influenza
patients revealed that peramivir clearance was linearly related to
CrCl when CrCl values were below 115 ml/min. On the other
hand, peramivir clearance was independent of CrCl when CrCl
values were over 115 ml/min (Matsuo et al., 2015). No difference
in PK was observed by gender, and the effects of age and body
weight on peramivir clearance were negligible (Food and Drug
Administration, 2015b; Matsuo et al., 2015). Peramivir clearance
was 18% higher and its distribution volume was 6% lower in
influenza patients compared to healthy volunteers. However,
these differences are not considered clinically significant (Matsuo
et al., 2015).
Additionally, the AUC of peramivir is highly dependent on
CrCl (Matsuo et al., 2015). In patients with moderate and severe
renal impairment exposure to peramivir upon IV administration
is expected to be increased by 3.4- and 6-fold, respectively,
compared to those with normal renal function (Chairat et al.,
2013). Therefore, dose adjustment based on renal function in
patients with renal impairment is required to provide AUCs
comparable to those in patients with normal renal function
(Table 2) (Chairat et al., 2013; Food and Drug Administration,
2015b; Matsuo et al., 2015). Using doses as high as 600 mg IV
once daily in patients with acute renal failure did not cause any
toxicity suggesting a high clearance of peramivir by continuous
renal replacement therapy (CRRT; Hernandez et al., 2011).
Accordingly, peramivir dose should be adjusted based on the type
and duration of CRRT provided. In a case report of an 18-year-
old male, peramivir was well cleared by continuous venovenous
hemofiltration with a half-life of 6.2 h (Scheetz et al., 2011).
Peramivir was also shown to be removed by hemodialysis, with
a 4-h hemodialysis reducing the systemic peramivir exposure
by 73–81% (Chairat et al., 2013). In patients with chronic renal
impairment maintained on hemodialysis, peramivir should be
administered after dialysis at a dose adjusted based on renal
function (Food and Drug Administration, 2015b).
TABLE 2 | Dosage adjustment for patients with altered creatinine clearance.
Renal function Mild renal impairment Moderate renal impairment Severe renal impairment
Creatinine clearance (mL/min) ≥50 30–49 10–29
Recommended dose (mg) 600 200 100
Source: Food and Drug Administration, 2015b.
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Two studies were conducted to evaluate PK interactions
between IV peramivir and other influenza antivirals (Atiee
et al., 2012). Concomitant administration of peramivir with oral
oseltamivir or rimantadine in humans did not adversely affect
their PK profile, demonstrating a lack of drug interaction.
Efficacy
Data from a double-blind, randomized, placebo-controlled study
evaluating oral peramivir administration in experimentally
infected influenza A or B patients, revealed a more pronounced
drop in virus titers, regardless of virus type, in the peramivir-
treated group compared to placebo (Iyer et al., 2002). These
data mirrored the success of oral peramivir for treatment and
prophylaxis of influenza infection in early animal studies (Bantia
et al., 2001; Sidwell et al., 2001a; Sweet et al., 2002). Driven by the
success of these studies, a phase III, double-blind, randomized,
placebo-controlled study examined the efficacy of oral peramivir
in treatment and prophylaxis of influenza A/H1N1 and B
infections (Barroso et al., 2005). In the prophylaxis arm, oral
peramivir was administered 24 h prior to virus inoculation and
continued for a total of 5 days. Only modest, non-significant
reductions in virus shedding were observed across all study
arms: 58% for placebo vs. 61, 37, and 31% for influenza A with
50, 100, and 200 mg q.d. (once daily) regimens, respectively;
55% for placebo vs. 31, 45, and 47% for influenza B with
200, 400, and 800 mg q.d. regimens, respectively (Barroso
et al., 2005). These values were in sharp contrast with those
for prophylactic oral oseltamivir regimens of 100 mg q.d. or
b.i.d. (twice daily), which completely prevented influenza A
virus shedding (Hayden et al., 1999). When peramivir was
administered orally 24 h after virus inoculation and continued for
a total of 5 days, significant reductions in influenza A and B virus
shedding rates were observed in treatment groups compared
with placebo (Barroso et al., 2005). However, this effect was
dose-dependent and was only observed with higher doses. The
group concluded that despite peramivir tolerability, the lack of
more robust antiviral effect is likely due to the relatively low
oral bioavailability (<3%) compared to oseltamivir (80%) and
recommended exploring alternative formulations or parenteral
administration.
Intramuscular peramivir was tested in two double-blind,
placebo-controlled studies in adult outpatients with acute,
uncomplicated influenza (Whitley et al., 2014). In the first
phase II clinical trial, 344 influenza patients were randomized to
three treatment groups: single-dose peramivir 150 mg, peramivir
300 mg, and placebo. In the phase III clinical trial, 83 influenza
patients were randomized to single-dose peramivir 300 mg and
placebo treatment groups. The phase III study was terminated
early to focus on evaluating more concentrated formulations of
peramivir. In both studies, peramivir was administered within
≤36 h of symptoms onset in 66–71% of participants who
were dominantly infected by H1N1 or H3N2 (Whitley et al.,
2014). An integrated analysis from both studies revealed that
a single-IM peramivir dose significantly shortened the time
to alleviation of symptoms (113.2 h for peramivir 300 mg)
compared to placebo (134.8 h); a difference of 20.7 h, adjusted
p = 0.047. For peramivir 150 mg, the difference was 21.6 h.
Similar reductions in the time to defervescence and resumption
of usual activities were reported with peramivir 300 mg compared
to placebo (Whitley et al., 2014). Subjects receiving 150 or
300 mg peramivir exhibited significantly lower proportions of
virus shedding on days 2 and 3 and lower virus titers on
day 3 compared to placebo. An improvement in the time
to alleviation of symptoms in patients treated with 150 or
300 mg peramivir was associated with a significant increase in
creatine kinase levels, a marker of successful IM administration
(Shetty and Peek, 2012). Thus, a follow-up phase II study was
conducted to evaluate to 600 mg peramivir administered as
bilateral 2-mL IM injections using longer needles (BioCryst
Pharmaceuticals, 2015). A total of 405 subjects with confirmed
influenza infections were randomized to receive placebo or
600 mg peramivir IM. The time to alleviation of symptoms did
not differ significantly between placebo (106.9 h) and 600 mg
peramivir (91.1 h; p = 0.22). The failure of treatment was
attributed to high prevalence of influenza A/H1N1 with H274Y
mutation conferring resistance to peramivir among the study
subjects (BioCryst Pharmaceuticals, 2015). Thus, a single-IM
peramivir administration failed to overcome resistance due the
H274Y mutation. Based on animal studies (Abed et al., 2011,
2012), multiple doses might be necessary to treat patients infected
with resistant viruses.
Several studies investigated the effect of IV peramivir as
single- or multiple-doses for treatment of influenza infection
(Kohno et al., 2010, 2011b; Ison, 2011; de Jong et al., 2014).
A phase II clinical trial evaluated the efficacy of single-dose IV
peramivir in previously healthy adults with confirmed influenza
infection (predominantly seasonal H1N1; Kohno et al., 2010).
Participants (n = 296) were randomized to receive 300 mg
peramivir, 600 mg peramivir or placebo within 48 h of symptoms
onset. IV peramivir 300 and 600 mg doses significantly reduced
time to alleviation of symptoms compared to placebo (300 mg
59.1 h, 600 mg 59.9 h, placebo 81.8 h; adjusted p-values= 0.0092
and 0.0092, respectively; Kohno et al., 2010). Defervescence was
evident as early as 24 h after treatment. The proportions of
subjects shedding virus were significantly smaller in the treatment
groups (300 mg 36.8% and 600 mg 35.8%) compared to placebo
(51.5%; p-values= 0.00485 and 0.0003, respectively; Kohno et al.,
2010).
A multinational, multicenter, phase III study enrolled 1091
subjects in Korea, Japan, and Taiwan (Kohno et al., 2011b).
The study compared single IV dose of peramivir (300 mg or
600 mg) to 5-day oral peramivir regimen (75 mg b.i.d.). Overall,
the time to alleviation of symptoms was similar across all study
groups: 300 mg peramivir, 78.0 h; 600 mg peramivir, 81.0 h; and
oseltamivir, 81.8 h. Despite the detection of the H274Y mutation
among nearly 100% of patients infected with H1N1 (Kohno et al.,
2011b), the time to alleviation of symptoms in the oseltamivir
group was well within the range reported in previous years
when oseltamivir-susceptible H1N1 was circulating (Nicholson
et al., 2000; Treanor et al., 2000). The authors concluded that
the significance of the study was not compromised due to the
lack of a placebo group, and that the efficacy of oseltamivir
was maintained despite the prevalence of the H274Y viruses
(Kohno et al., 2011b). In the H3N2-infected subgroup of patients,
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peramivir (300 and 600 mg doses) was as effective as oseltamivir.
Surprisingly, the 300 mg but not 600 mg peramivir dose resulted
in significantly shorter time to alleviation of symptoms compared
to oseltamivir in the influenza B subgroup (55.3, 92.8, and 92.7 h,
respectively; Kohno et al., 2011b). A smaller scale study including
32 patients hospitalized for influenza A infections in 2012 also
found no significant difference in the time to defervescence
between peramivir and oseltamivir groups (Yoshino et al.,
2015).
Further studies assessed the efficacy of multiple doses of
peramivir in severely ill or hospitalized patients. In a phase
II study, Ison et al. (2013) enrolled 122 hospitalized influenza
patients who were randomized to receive IV 200 or 400 mg
peramivir q.d. or oral 75 mg oseltamivir b.i.d. for 5 days. The
study found no significant difference in the time to clinical
stability among the three treatment groups: 200 mg peramivir,
23.7 h; 400 mg peramivir, 37.0 h; and oseltamivir, 28.1 h. A post
hoc analysis of clinical outcome of clinically unstable patients
(n = 97) revealed similar findings (Ison et al., 2013). Consistent
with earlier findings, a retrospective analysis of severely ill
patients with influenza found IV peramivir to be as effective
as oral oseltamivir treatment (Yoo et al., 2015). A phase III,
open-label, multinational, clinical trial was conducted during
the H1N1pdm09 to assess the antiviral activity of two dosing
regimens of IV peramivir (300 mg b.i.d. or 600 mg q.d. for
5 days; Ison et al., 2014). The median time to resolution of
symptoms was 45 h for 300 mg peramivir (n = 57) and 166 h
for 600 mg peramivir (n = 70). Nonetheless, it was noted
that the 600 mg group had more patients with severe disease
(i.e., baseline need for ICU admission, need for supplemental
oxygen, or high APACHE score), which might have attributed
to the longer time to symptoms relief. No significant difference
in the time-weighted change in virus titer from baseline to
48 h was observed between the treatment groups (Ison et al.,
2014).
In high risk patients, defined as those with ≥1 risk factors
and ≥2 moderate to severe influenza symptoms; n = 37),
single-dose IV peramivir (300 or 600 mg) was assessed with
additional administrations delivered as needed up to 5 days
(Kohno et al., 2011a). The median time to alleviation of illness
was significantly longer for the 300 mg peramivir (114.4 h)
compared to the 600 mg dose (42.3 h). Another phase III
double-blind, randomized clinical trial, assessed the efficacy of
multi-dose peramivir in hospitalized patients (de Jong et al.,
2014). Of 1600 subjects screened, 338 subjects with confirmed
influenza (A or B) were included in the intent to treat influenza
(ITTI) population. Patients were randomized to receive placebo
or 600 mg IV peramivir q.d. for 5 days, in addition to the
institution’s standard of care (SOC) treatment. The non-NAI
SOC ITTI (did not receive concurrent NAI) population included
121 patients and the remaining 217 belonged to the NAI
SOC (216 received oseltamivir and 1 received zanamivir) ITTI
population (de Jong et al., 2014). The median time to clinical
resolution did not differ significantly between peramivir and
placebo (42.5 h vs. 49.5 h, respectively; p = 0.97) in the non-
NAI SOC population. Similar data were observed for the NAI
SOC population. An improved treatment outcome was observed
in subjects enrolled within <48 h or those admitted to intensive
care unit (ICU). However, the difference in time to clinical
resolution between placebo and peramivir groups did not reach
statistical significance due to the limited sample size and the
study was terminated (de Jong et al., 2014). With the exception
of this study, studies in severely ill patients are undermined by
the lack of a placebo group, which is not possible in high risk
populations.
Currently, IV peramivir is approved for use in children
<18-year-old in Japan. The approval of peramivir in Japan
was based on a multicenter, open-label, uncontrolled clinical
study demonstrating efficacy and safety of IV peramivir in
children (Sugaya et al., 2012). Children with confirmed influenza
infection during the H1N1pdm09 and ranging in age between
≥28 days to<16 years were enrolled. Peramivir was administered
as IV infusion at 10 mg/kg (600 mg maximum dose in
children with ≥60 kg body weight). The median time to
alleviation of symptoms was 29.1 h and virus shedding was
confirmed in 78.2 and 7.1% of children on days 2 and 6
after initiation of treatment, respectively (Sugaya et al., 2012).
Hikita et al. (2012) compared the efficacy of IV peramivir
(10 mg/kg, max 300 mg per dose) with other NAIs. For
influenza A patients, the median duration of fever was 1 day
for peramivir and 2 days for zanamivir (p = 0.0242). In
the case of influenza B, the median duration of fever was
also 1 day for peramivir compared to 3 days for laninamivir
(p = 0.0097). These results suggest that peramivir is also useful
in children, especially where the use of inhalation drugs is not
feasible.
Safety
Overall, peramivir demonstrated good tolerability and safety
in all clinical studies (Kohno et al., 2010, 2011b; Ison et al.,
2013, 2014; Whitley et al., 2014). Post-marketing evaluation
of peramivir under routine clinical settings mirrored the
clinical trials in terms of safety and effectiveness in adults
and pediatrics (Komeda et al., 2014, 2015). Most reported
adverse events (AEs) were mild to moderate in severity and
were more common in young children (Kohno et al., 2011a;
Sugaya et al., 2012; de Jong et al., 2014; Ison et al., 2014;
Whitley et al., 2014) and their frequency was comparable to
placebo (Kohno et al., 2010; Whitley et al., 2014). Peramivir
AEs were similar in severity and frequency to those reported
for oral oseltamivir (Kohno et al., 2011a; Ison et al., 2013),
and generally occurred within 3 days of initiating treatment
and rapidly subsided (Sugaya et al., 2012). The frequency
of AEs was similar regardless of the number of doses
received.
The most common AEs were gastrointestinal disorders
including diarrhea (mild to moderate), nausea, and vomiting
(Kohno et al., 2011a; Sugaya et al., 2012; Ison et al., 2013; de
Jong et al., 2014; Komeda et al., 2014, 2015; Whitley et al.,
2014). Komeda et al. (2015) reported that abnormal behavior,
cough, and pyrexia were among the common AEs in pediatrics
along with GI disorders. The majority of serious AEs were found
to be related to influenza infection (e.g., pneumonia, chronic
obstructive pulmonary disorder; de Jong et al., 2014). The most
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common severe AEs were decrease in neutrophil count (lowest
mainly on day 3) and prolonged QT interval; however, these
returned to normal without any intervention (Kohno et al., 2010,
2011a; Sugaya et al., 2012; Komeda et al., 2014, 2015).
Some rare but severe AEs were also reported upon
treatment with peramivir. A 44-year-old man with
history of lower than normal platelet count had severe
thrombocytopenia that was possibly elicited by peramivir
(Harada-Shirado et al., 2014). This was confirmed by drug-
induced lymphocyte-stimulating test which was positive for
peramivir. Hayashi et al. (2015) described a case of exacerbated
myasthenia gravis in a 73-year-old women triggered by IV
peramivir.
FDA APPROVAL
Given its well-established efficacy and safety, the FDA granted
approval for IV peramivir under the brand name RapivabTM
on December 19, 2014 (Food and Drug Administration, 2015b).
Under the FDA approval, peramivir is indicated for treatment
of acute uncomplicated influenza in patients 18 years and
older who have been symptomatic for no more than 2 days.
The recommended dose is 600 mg administered once via
IV infusion for 15–30 min within 48 h of symptoms onset.
Peramivir must be diluted prior to administration. In case of
renal impairment, the recommended dose is lowered to 200 mg
for patients with creatinine clearance 30–49 mL/min and to
100 mg for patients with creatinine clearance 10–29 mL/min
(Table 2).
EMERGENCY USE AUTHORIZATION
On October 23, 2009 upon request from the Centers for
Disease Control and Prevention (CDC), the FDA issued an
emergency use authorization (EUA) for IV peramivir while
still an investigational antiviral drug, in hospitalized patients
with H1N1pdm09 infection (Food and Drug Administration,
2015a). IV peramivir could only be used for hospitalized adult
and pediatric patients who were not responsive to approved
antivirals, or where delivery by alternative route (oral or inhaled)
was not feasible. The EUA was effective through June 23,
2010. During this period, the CDC received 1371 requests for
IV peramivir and 1274 hospitalized patients received ≥1 dose
(median duration = 6 days; Yu et al., 2012). Under the EUA
all AEs were to be reported to the FDA. Sorbello et al. (2012)
reviewed 344 AE reports to evaluate the safety of IV peramivir
treatment in hospitalized patients under the EUA. Many of the
patients were severely ill requiring mechanical ventilation and/or
renal replacement therapy. The most commonly reported AEs
were death (18%), respiratory failure (8%), acute renal failure
(7%), and acute respiratory distress syndrome (7%). But these
AEs were not considered to be caused by IV peramivir and
were thought to be a direct outcome of influenza infection
induced illnesses. Death was mainly associated with other risk
factors (i.e., obesity, immunosuppressed, or aged >65 years;
Sorbello et al., 2012). Rash was the only AE attributed to
peramivir and was reported in 13 cases. Hernandez et al.
(2011) reviewed data for 31 adult (including pregnant women)
and pediatric hospitalized patients with severe H1N1pdm09
viral pneumonia who received IV peramivir during the EUA
(Hernandez et al., 2011). The study concluded that the drug
was generally well tolerated and associated with complete
recovery.
A survey of the public acceptance of peramivir use under
the EUA revealed that 48% of the participants would probably
or definitely take peramivir (Quinn et al., 2015). Seventy-
nine percent indicated that they would definitely take it if
recommended by their physician or no alternative treatments
were available. Willingness to take peramivir increased with
increased illness severity and was also affected by the individual’s
trust in government actions (Quinn et al., 2015). Therefore,
providing patients with relevant information on efficacy and
safety of peramivir as well as potential risk of influenza
complications is likely to improve patients’ acceptance of
treatment.
CONCLUSION
Peramivir is a highly potent inhibitor against influenza A and B
viruses with a well-demonstrated safety profile. Administration
via IV route provides an alternative for patients who cannot
use oral drugs. Common side effects include gastrointestinal
disorders and decreased neutrophil count and are self-limiting.
While currently only approved for treatment of uncomplicated
influenza in adults, clinical studies and post-marketing efficacy
and safety data in pediatric populations provide promise for
the potential of approval of peramivir in this highly susceptible
population. The potential for emergence of resistant viruses and
cross-resistance with oseltamivir remains a challenge for clinical
practice. This highlights the need for continual development of
antivirals targeting other influenza virus or host proteins while
monitoring the effectiveness of existing drugs.
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